Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats

a quantitative study

Ludmila Belayev, Raul Busto, Brant D. Watson, Myron Ginsberg

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

We examined the effect of HU-211, a synthetic non-psychotropic cannabinoid with non-competitive N-methyl-d-aspartate (NMDA) antagonist properties, on blood-brain barrier (BBB) integrity after photochemically induced cortical infarction. Evans blue dye was used as a BBB permeability indicator after unilateral thrombotic cortical infarction was produced photochemically by 560 nm light irradiation of the cortex in male Wistar rats receiving rose bengal intravenously. HU-211 was injected in a dose of 4 mg/kg i.v. 30 min after stroke. Fluorometric measurement of Evans blue was performed 24 h later in six brain regions. Treatment with HU-211 significantly decreased extravasation of dye into the area of infarct (406 ± 19 vs. 539 ± 33 μg/g, mean ± S.E.M.) as well as other sites of the affected hemisphere (866 ± 68 vs. 1096 ± 68 μg/g compared to the vehicle group. These data indicate that HU-211 is an effective drug in protecting against the effects of focal ischemia-induced BBB disruption in the rat and suggest that the drug may be an effective treatment against the ischemic cell death and BBB disruption that can occur clinically following a stroke or cardiac arrest.

Original languageEnglish
Pages (from-to)266-270
Number of pages5
JournalBrain Research
Volume702
Issue number1-2
DOIs
StatePublished - Dec 8 1995

Fingerprint

Blood-Brain Barrier
Aspartic Acid
Infarction
Evans Blue
Coloring Agents
Stroke
Rose Bengal
Cannabinoids
Heart Arrest
Pharmaceutical Preparations
Wistar Rats
Permeability
Cell Death
Ischemia
Light
HU 211
Brain

Keywords

  • Blood-brain barrier
  • Evans blue
  • HU-211
  • Photochemical cortical infarction

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats : a quantitative study. / Belayev, Ludmila; Busto, Raul; Watson, Brant D.; Ginsberg, Myron.

In: Brain Research, Vol. 702, No. 1-2, 08.12.1995, p. 266-270.

Research output: Contribution to journalArticle

@article{87c7e7aafc534714917ce337eb217522,
title = "Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats: a quantitative study",
abstract = "We examined the effect of HU-211, a synthetic non-psychotropic cannabinoid with non-competitive N-methyl-d-aspartate (NMDA) antagonist properties, on blood-brain barrier (BBB) integrity after photochemically induced cortical infarction. Evans blue dye was used as a BBB permeability indicator after unilateral thrombotic cortical infarction was produced photochemically by 560 nm light irradiation of the cortex in male Wistar rats receiving rose bengal intravenously. HU-211 was injected in a dose of 4 mg/kg i.v. 30 min after stroke. Fluorometric measurement of Evans blue was performed 24 h later in six brain regions. Treatment with HU-211 significantly decreased extravasation of dye into the area of infarct (406 ± 19 vs. 539 ± 33 μg/g, mean ± S.E.M.) as well as other sites of the affected hemisphere (866 ± 68 vs. 1096 ± 68 μg/g compared to the vehicle group. These data indicate that HU-211 is an effective drug in protecting against the effects of focal ischemia-induced BBB disruption in the rat and suggest that the drug may be an effective treatment against the ischemic cell death and BBB disruption that can occur clinically following a stroke or cardiac arrest.",
keywords = "Blood-brain barrier, Evans blue, HU-211, Photochemical cortical infarction",
author = "Ludmila Belayev and Raul Busto and Watson, {Brant D.} and Myron Ginsberg",
year = "1995",
month = "12",
day = "8",
doi = "10.1016/0006-8993(95)01127-9",
language = "English",
volume = "702",
pages = "266--270",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats

T2 - a quantitative study

AU - Belayev, Ludmila

AU - Busto, Raul

AU - Watson, Brant D.

AU - Ginsberg, Myron

PY - 1995/12/8

Y1 - 1995/12/8

N2 - We examined the effect of HU-211, a synthetic non-psychotropic cannabinoid with non-competitive N-methyl-d-aspartate (NMDA) antagonist properties, on blood-brain barrier (BBB) integrity after photochemically induced cortical infarction. Evans blue dye was used as a BBB permeability indicator after unilateral thrombotic cortical infarction was produced photochemically by 560 nm light irradiation of the cortex in male Wistar rats receiving rose bengal intravenously. HU-211 was injected in a dose of 4 mg/kg i.v. 30 min after stroke. Fluorometric measurement of Evans blue was performed 24 h later in six brain regions. Treatment with HU-211 significantly decreased extravasation of dye into the area of infarct (406 ± 19 vs. 539 ± 33 μg/g, mean ± S.E.M.) as well as other sites of the affected hemisphere (866 ± 68 vs. 1096 ± 68 μg/g compared to the vehicle group. These data indicate that HU-211 is an effective drug in protecting against the effects of focal ischemia-induced BBB disruption in the rat and suggest that the drug may be an effective treatment against the ischemic cell death and BBB disruption that can occur clinically following a stroke or cardiac arrest.

AB - We examined the effect of HU-211, a synthetic non-psychotropic cannabinoid with non-competitive N-methyl-d-aspartate (NMDA) antagonist properties, on blood-brain barrier (BBB) integrity after photochemically induced cortical infarction. Evans blue dye was used as a BBB permeability indicator after unilateral thrombotic cortical infarction was produced photochemically by 560 nm light irradiation of the cortex in male Wistar rats receiving rose bengal intravenously. HU-211 was injected in a dose of 4 mg/kg i.v. 30 min after stroke. Fluorometric measurement of Evans blue was performed 24 h later in six brain regions. Treatment with HU-211 significantly decreased extravasation of dye into the area of infarct (406 ± 19 vs. 539 ± 33 μg/g, mean ± S.E.M.) as well as other sites of the affected hemisphere (866 ± 68 vs. 1096 ± 68 μg/g compared to the vehicle group. These data indicate that HU-211 is an effective drug in protecting against the effects of focal ischemia-induced BBB disruption in the rat and suggest that the drug may be an effective treatment against the ischemic cell death and BBB disruption that can occur clinically following a stroke or cardiac arrest.

KW - Blood-brain barrier

KW - Evans blue

KW - HU-211

KW - Photochemical cortical infarction

UR - http://www.scopus.com/inward/record.url?scp=0028973635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028973635&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(95)01127-9

DO - 10.1016/0006-8993(95)01127-9

M3 - Article

VL - 702

SP - 266

EP - 270

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -